Cover Image
Market Research Report - 238169

Stem Cell Research Products - Opportunities, Tools, and Technologies

Published Content info 155 Pages
Back to Top
Stem Cell Research Products - Opportunities, Tools, and Technologies
Published: June 1, 2014 Content info: 155 Pages


Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type.

Stem cells are still a relatively new discovery, as the first mouse embryonic stem cells were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts. In 2006, induced pluripotent stem cells were produced for the first time from mouse cells and in 2007 they were produced from human cells. Furthermore, it was not until 2008 that the first full transplant of a human organ grown from adult stem cells was performed when a section of trachea was successfully transplanted into an adult woman in Spain.

As of 2014, several broad categories of stem cells exist, including:

  • Embryonic stem cells, derived from blastocysts
  • Fetal stem cells, obtained from fetuses
  • Post-natal stem cells, derived from newborn tissues
  • Adult stem cells, found in adult tissues - including Hematopoietic stem cells, Mesenchymal stem cells, and Neural stem cells
  • Cord blood stem cells, isolated from umbilical tissue
  • Dental stem cells, derived from deciduous teeth
  • Induced pluripotent stem cells, reprogrammed from adult cells
  • Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body
  • Animal stem cells, derived from non-human sources

The past 10 years have also witnessed the production of novel stem cell types, including piPSCs, R-NSCs, and VSELs. Together, this evidence suggests that additional types of stem cells will likely be discovered, each representing new opportunities for research product development. Clearly, laboratory research into stem cell derivation, manipulation, and application is rapidly expanding.

To facilitate research resulting from these advances, a large and diverse stem cells products market has emerged. Large companies selling stem cell research products include Thermo Fisher Scientific (now merged with Life Technologies), BD Biosciences, EMD Millipore, Sigma Aldrich, and STEMCELL Technologies, as well as over one hundred other suppliers.

Currently, the following product categories compose the majority of global stem cell product sales:

  • Primary antibodies to stem cell antigens
  • Bead-based stem cell separation systems
  • Fluorescent-based labeling and detection
  • Stem cell protein purification and analysis tools
  • Tools for DNA and RNA-based characterization of stem cells
  • Isolation/characterization services
  • Stem cell culture media and reagents
  • Stem cell specific growth factors and cytokines
  • Tools for stem cell gene regulation
  • Stem cell services and mechanisms for in vivo and in vitro stem cell tracking
  • Expansion/differentiation services for stem cell media and RNAi
  • Stem cell lines

Furthermore, to sell products in the stem cell market, it is critical to understand the research applications for which stem cells are being studied. One area of study is the use of stem cells to understand and treat birth disorders. However, of greater interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders.

Pharmaceutical companies have intense interest in the ability to use stem cells to improve drug target validation and toxicology screening. Therefore, it is important for companies interested in stem cell therapy applications to understand underlying market forces, and in particular, to consider progressive areas of stem cell research as opportunistic areas for drug and therapy development. This report presents a range of topics of interest to these companies as well, including how advances in stem research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

The key areas that account for the majority of applied stem cell research include:

  • Regenerative Medicine - Reversal of injury or disease
  • Drug Target Validation and Drug Delivery - Treatment of disease
  • Toxicology Screening - Drug safety and efficacy assessment
  • Understanding and Treatment of Birth Disorders - Natal repair

This 2014 report provides detailed information on both basic and applied stem cell research and research applications and includes an updated list of global stem cell research centers by region.

Furthermore, it is crucial for stem cell companies to understand the funding environment that supports stem cell research. Currently, the U.S. federal government is an important, although not dominant, source of funding for stem cell research. The reason is that U.S. states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge amount of funding, with analysis of recent large gifts summing to over $1.7 billion.

Growth in stem cell research has exploded in the past decade, and so the market to supply stem cell research products has grown to meet this huge demand. There are now over one million stem cell researchers worldwide. In addition, there were only 17 stem cell product companies as of 2006, and that has expanded to more than 100 today, a 6-fold increase.

The two most active areas of stem cell research are mesenchymal stem cells, at 24.8% of all stem cell research, and hematopoietic stem cells, at 24.1% - thus accounting for nearly half of all stem cell research over a trailing twelve-month period. When this analysis was last conducted using data from full-year 2012 (Jan 1, 2012 - Dec 31, 2012), hematopoietic stem cell research led mesenchymal stem cell research, but that relationship has since switched, revealing an interesting preference toward mesenchymal stem cell research among the scientific community.

Also of interest is that for the trailing-twelve months, induced pluripotent stem cell research activity represented 8.9% of global stem cell research activity. When this analysis was last conducted using full-year 2012 data (Jan 1, 2012 - Dec 31, 2012), induced pluripotent stem cell research activity represented only 4.0% of global research activity, which means that a substantial year-over-year shift has occurred. This report explores why this trend has developed and how it will continue to evolve in the coming decade.

Not surprisingly, trend analysis reveals rapid increases in stem cell research activity over the past five years, specifically a scientific publication rate increase of 9.9% per year.

The stem cell types with the greatest year-to-year increases in publication rates over a trailing five-year period include:

  • Mesenchymal stem cells
  • Induced pluripotent stem cells
  • Neural stem cells

While hematopoietic stem cells represent the second most active area of stem cell research, publication rates for these stem cell types have declined in recent years. Because research activity by stem cell type has shown divergent trends over the past few years, for research product companies to be successful, they will need to understand underlying trends in stem cell preferences, by cell type.

This market intelligence report will advantageously position your company to offer competitive stem cell products to a rapidly growing, well-funded research community.

End-User Survey of Stem Cell Scientists:

A key element of this report is a survey of stem cell researchers, for the U.S. and worldwide. This 2014 survey reveals stem cell researcher needs, technical preferences, key factors influencing buying decisions, and more. It can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

To benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.

This survey reveals critical findings that include:

  • Prevalence of Stem Cell Research by Cell Type
  • Stem Cell Product Preferences
  • Most Commonly Utilized Stem Cell Markers, by Stem Cell Type
  • Most Commonly Utilized Stem Cell Antibodies, by Stem Cell Type
  • Preferred Providers of Stem Cell Antibodies
  • And Much More

Summary of Findings:

There is conclusive evidence that entering the stem cell research products market is financially worthwhile. Full-year 2013 analysis determines the size of the stem cell research products market to be $3.22 billion, and the stem cell therapies market to be $3.31 billion, for a total of $6.53 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies.

Additionally, the industry insights contained in this market report will allow you to dramatically increase your profits within the stem cell sector.

Key findings within the report include:

  • Charts, Timelines, and Financials for the Stem Cell Product Market
  • Breakdown of Research Activity by Application, Species, Tissue Source
  • Geographical Assessment of Market Demand
  • Trend Data and Rate Analysis for Stem Cell Grants, Scientific Publications, and Patents
  • Market Size Determinations for Stem Cell Research Products
  • Market Size Determinations for Related Markets - Stem Cell Antibodies and Stem Cell Therapies
  • 5-Year Market Size Projections (2014-2018)
  • Competitive Environment Analysis, Including Identification of Market Leaders
  • Preferred Species for Stem Cell Research
  • Breakdown of Stem Cell Product Categories
  • Recent Product Evolution and Unmet Market Needs
  • Breakdown of the Marketing Methods Used by Industry Participants
  • Key Survey Findings from Your Prospective Clients - Stem Cell Scientists
  • End-User Wants, Technical Preferences, Factors Influencing Buying Decisions
  • And Much More

Producing stem cell products can involve complicated and confusing decisions, but it doesn't have to. Claim this report to reveal the current and future needs of your customer base, so you can focus your marketing efforts on the most profitable products, in the most promising research areas and within the most lucrative domestic and international markets.

Your competitors would prefer you didn't buy this report. But when you do, you'll be gaining invaluable stem cell market insights to help you control and dominate this market.


Stem Cell Publications by Year
(Search Terms = "Stem Cell" or "Stem Cells")

Table of Contents

Table of Contents



  • A. Human Embryonic Stem Cells (hESCs)
    • 1. Early, 5-7 days (totipotent)
    • 2. Gonadal Ridge, 6 months (multipotent)
  • B. Fetal Stem Cells (pluripotent)
  • C. Umbilical Cord Stem Cells (multipotent)
    • 1. Cord Blood
    • 2. Cord Matrix (“Wharton's Jelly”)
  • D. Dental Stem Cells (multipotent)
  • E. Adult Stem Cells (multipotent)
    • 1. Hematopoietic Stem Cells
    • 2. Mesenchymal Stem Cells
    • 3. Neural Stem Cells
  • F. Cancer Stem Cells (multipotent)
  • G. Induced Pluripotent Stem Cells (iPSCs)
  • H. Novel (recently discovered and uncharacterized) Stem Cell Types
    • 1. Neural Rosette Cells (R-NSCs)
    • 2. Very Small Embryonic Like (VSEL) Stem Cells


  • A. Regenerative Medicine (Cell-Based Therapies)
    • 1. Diabetes Mellitus
    • 2. Cardiovascular Disease
    • 3. Neurological Disease
    • 4. Autoimmune Disease
    • 5. Hematopoietic Disease and Transplantation Research
    • 6. Orthopedic Repair
    • 7. Cancer Research
    • 8. Birth Defect Research
  • B. Drug Development & Discovery
    • 1. Assays to Aid Early Stage Discovery
    • 2. Improved Prediction of Human Responses
    • 3. Drug Development with Humanized Mouse Models
    • 4. Genetically-Engineered Stem Cell Lines for Screening
    • 5. Pluripotent Stem Cell Lines for Target Validation and Drug Screening
    • 6. Summary - Use of Stem Cells in Drug Development & Discovery


  • A. Life Technologies (Invitrogen Brand)
    • 1. Stem Cell Products
      • a. Isolation and Characterization Products
      • b. Expansion and Differentiation Products
    • 2. Strategic Collaborations
      • a. Cellartis AB
      • b. Novocell
      • c. The Buck Institute
  • B. BD Biosciences
    • 1. Stem Cell Products
      • a. Isolation
      • b. Culturing
      • c. Analysis
    • 2. Collaborations: BD Biosciences and STEMCELL Technologies
  • C. Comparison of Stem Cell Publication Rates: Invitrogen Brand Products (Life Technologies) versus BD Biosciences


  • A. Primary Antibodies
  • B. Bead-based Cell Separations Systems
  • C. Fluorescent-based Labeling and Detection
  • D. Protein Purification and Analysis Tools
    • 1. Protein Purification
    • 2. Stem Cell Protein Analysis
    • 3. Quantitative Proteomics
  • E. DNA/RNA Based Characterization
    • 1. Tools for DNA- and RNA-based Characterization
    • 2. Stem Cell HLA Typing
    • 3. Stem Cell Nucleic Acid Extraction and Purification, PCR/qRT-PCR Reagents
  • F. Isolation / Characterization Services
    • 1. Stem Cell HLA Typing Services
    • 2. Stem Cell Custom Services
    • 3. Stem Cell Custom Antibodies
  • G. Stem Cell Culture Media and Reagents
  • H. Growth Factors and Cytokines
  • I. Stem Cell Gene Regulation
  • J. In vivo / In vitro Stem Cell Tracking
  • K. Expansion / Differentiation Services
    • 1. Stem Cell Media Services
    • 2. RNAi Services
  • L. Stem Cell Lines


  • A. Definition: Stem Cell Research Products
  • B. Experimental Approach
  • C. Stem Cell Research Products, Market Size (in Millions)
  • D. Stem Cell Antibodies, Market Size (in Millions)
  • E. Stem Cell Therapies, Market Size (in Billions)


  • A. Breakdown of Research Segments by End-user Application
    • 1. Basic Research
    • 2. Applied Research
      • a. Autologous and Allogeneic Cell Therapy
      • b. Toxicology Screening for Drug Discovery and Development
  • B. Breakdown of Stem Cell Research by Cell Type
    • 1. Cord Blood Stem Cells
    • 2. Dental Stem Cells
    • 3. iPSCs
  • C. Breakdown of Stem Cell Research by Species
  • D. Publication Rate Analysis
    • 1. Overview of Stem Cell Publication Rates
    • 2. Comparative Analysis of Stem Cell Publication Trends
  • E. Sources of Stem Cell Funding
    • 1. Federal
    • 2. State
    • 3. Private
  • F. Patent Analysis
  • G. Geographical Analysis: Domestic vs. International Status


  • A. Survey Overview
  • B. Characterization of Market Survey Respondents
    • 1. Geographic Distribution of Respondents
    • 2. Respondent Breakdown by Industry Affiliation
    • 3. Breakdown of Respondents by Duration of Stem Cell Activity
  • C. Survey Findings - General Scope
  • D. Survey Findings - Applied Stem Cell Research
  • E. Survey Findings - Dominant Stem Cell Markers
  • F. Survey Findings - Market Penetration of Stem Cell Markers, by Cell Type
    • 1. Human Embryonic Stem Cells (hESCs)
    • 2. Mesenchymal Stem Cells (MSCs)
    • 3. Neural Stem Cells (NSCs)
    • 4. Hematopoietic Stem Cells (HSCs)
  • G. Survey Findings - Preferred Providers of Stem Cell Antibodies


  • A. Top Research Institutions Performing Stem Cell Research
    • 1. University of Wisconsin, including WARF, WiCell, and the WISC Bank
    • 2. Johns Hopkins University
    • 3. US National Institutes of Health (NIH)
    • 4. California Institute for Regenerative Medicine
  • B. Events of Interest


Back to Top